Interpreting Non-Inferiority Across Effect Scales: A Bayesian Perspective with Clinical Translation.

Ther Innov Regul SciMay 14, 2026 (epub)
Clinical ResearchPediatricsOpen access

Danila Azzolina, Silvia Bressan, Mohd Rashid Khan et al.

✦ AI-curated · Sources linked

In 30 seconds

This study conducted a secondary Bayesian reanalysis of a randomized controlled trial comparing high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV) in infants with acute bronchiolitis. The analysis revealed that a non-inferiority margin of 0.15 in absolute risk reduction could imply a doubling of intubation odds, with a Number Needed to Harm of approximately 6.7.

Key findings

  • The Bayesian reanalysis indicated that a 0.15 non-inferiority ARR margin might imply a doubling of the odds of intubation.
  • The Number Needed to Harm (NNH) for HFNC compared to NIV was approximately 6.7.
  • The original analysis concluded non-inferiority using a fixed absolute margin.

Why it matters

Understanding the implications of non-inferiority margins is crucial for clinicians when interpreting trial results, as these margins can significantly affect treatment decisions and patient outcomes.

Source

PubMed · PMID 42133236Free full text on PubMed Central

Published in Ther Innov Regul Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.